nmpЖурнал им. Н.В. Склифосовского «Неотложная медицинская помощь»Russian Sklifosovsky Journal "Emergency Medical Care"2223-90222541-8017“N.V. Sklifosovsky Research Institute for Emergency Medicine”10.23934/2223-9022-2021-10-4-769-777nmp-1282Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWSАнтиагрегантная терапия при остром коронарном синдромеAntiplatelet Therapy in Acute Coronary Syndromehttps://orcid.org/0000-0001-9458-7305КузьминаИ. М.KuzminaI. M.

кандидат медицинских наук, врач-кардиолог, руководитель научного отделения неотложной кардиологии для больных с острым инфарктом миокарда,

129090, Москва, Б. Сухаревская пл., д. 3

Candidate of Medical Sciences, Cardiologist, Head of the Scientific Department of Emergency Cardiology for  Patients with Acute Myocardial Infarction,

3 Bolshaya Sukharevskaya Square, Moscow 129090

kuzmina.sklif@gmail.comhttps://orcid.org/0000-0002-0064-432XМархулияД. С.MarkhuliyaD. S.

врач анестезиолог-реаниматолог отделения реанимации и интенсивной терапии,

129090, Москва, Б. Сухаревская пл., д. 3

Anesthesiologist-resuscitator of the Department of Resuscitation and Intensive Care,

3 Bolshaya Sukharevskaya Square, Moscow 129090

ninidzed@gmail.comhttps://orcid.org/0000-0002-6240-820XПопугаевК. А.PopugayevK. A.

доктор медицинских наук, заместитель директора — руководитель Регионального сосудистого центра,

129090, Москва, Б. Сухаревская пл., д. 3

Doctor of Medical Sciences, Deputy Director – Head of the Regional Vascular Center,

3 Bolshaya Sukharevskaya Square, Moscow 129090

popugaevka@sklif.mos.ruhttps://orcid.org/0000-0002-2667-6477КиселевК. В.KiselevK. V.

старший бизнес-аналитик, 

123112, Москва, 1-й Красногвардейский пр., д. 21, стр. 1

Senior Business Analyst, 

21 bld. 1 Krasnogvardeisky 1-y pr., Moscow 123112

kirillkiselev@protonmail.comГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского ДЗМ»РоссияN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentRussian FederationГКУ «Информационно-аналитический центр в сфере здравоохранения» г. МосквыРоссияHealth Information and Analytical CenterRussian Federation202121012022104769777Copyright © Кузьмина И.М., Мархулия Д.С., Попугаев К.А., Киселев К.В., 20222022Кузьмина И.М., Мархулия Д.С., Попугаев К.А., Киселев К.В.Kuzmina I.M., Markhuliya D.S., Popugayev K.A., Kiselev K.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jnmp.ru/jour/article/view/1282

Сердечно-сосудистые заболевания в настоящее время являются наиболее частой причиной смертности во всем мире, а среди смертей от сердечно-сосудистых заболеваний большинство связано с ишемической болезнью сердца (ИБС). ИБС в целом представляет собой серьезную проблему для населения в мире, а острый коронарный синдром (ОКС) ассоциирован с высокой заболеваемостью, смертностью и ложится большим финансовым бременем на систему здравоохранения. Это неотложная ситуация, при которой диагностические и лечебные мероприятия должны выполняться как можно скорее от момента начала заболевания. Диагностика ОКС начинается с тщательной клинической оценки имеющихся у пациента симптомов, электрокардиограммы и уровня в крови тропонина, а также изучения анамнеза заболевания. Ключевые компоненты в лечении ОКС включают коронарную реваскуляризацию при наличии показаний и быстрое начало адекватной антиагрегантной терапии. Представленный обзор литературы посвящен проблемам проведения адекватной антиагрегантной терапии у пациентов с ОКС. 

Cardiovascular diseases are currently the most common causes of death worldwide, and most deaths from cardiovascular diseases are associated with coronary artery disease (CAD). CAD as a whole is a serious problem for the world’s population, and acute coronary syndrome (ACS) is associated with high morbidity, mortality and a great financial burden on the health care system. This is an urgent situation in which diagnostic and treatment measures must be performed as soon as possible from the moment of onset of the disease. Diagnosis of ACS begins with a thorough clinical assessment of the patient’s symptoms, electrocardiogram and blood troponin levels, as well as a history of the disease. Key components in the treatment of ACS include coronary revascularization when indicated and prompt initiation of adequate antiplatelet therapy. The presented literature review is devoted to the problems of adequate antiplatelet therapy in patients with ACS. 

острый коронарный синдромОКСспSTОКСбпSTтромбообразованиеантиагрегантная терапиядвойная антитромбоцитарная терапия (ДАТТ)эскалациядеэскалацияacute coronary syndromeSTE-ACSNSTE-ACSthrombosisantiplatelet therapydual antiplatelet therapy (DAPT)escalationde-escalationReferencesCamm AJ, Lüscher TF, Maurer G, Serruys PW. (eds.) ESC CardioMed. 3rd ed. Oxford University Press; 2018. https://doi.org/10.1093/med/978019 8784906.001.0001Camm AJ, Lüscher TF, Maurer G, Serruys PW. (eds.) ESC CardioMed. 3rd ed. Oxford University Press; 2018. https://doi.org/10.1093/med/9780198784906.001.0001Здравоохранение в России 2015: статистический сборник. Москва: Росстат; 2015.Zdravookhranenie v Rossii 2015: statisticheskiy sbornik. Moscow: Rosstat Publ.; 2015. (in Russ.)Braunwald E, Morrow DA. Unstable Angina: Is It Time for a Requiem? Circulation. 2013;127(24):2452–2457. PMID: 23775194 https://doi.org/10.1161/CIRCULATIONAHA113.001258Braunwald E, Morrow DA. Unstable Angina: Is It Time for a Requiem? Circulation. 2013;127(24):2452–2457. PMID: 23775194 https://doi.org/10.1161/CIRCULATIONAHA.113.001258Sheridan PJ, Crossman DC. Critical review of unstable angina and nonST elevation myocardial infarction. Postgrad Med J. 2002;78(926):717– 726. PMID: 12509688 https://doi.org/10.1136/pmj.78.926.717Sheridan PJ, Crossman DC. Critical review of unstable angina and nonST elevation myocardial infarction. Postgrad Med J. 2002;78(926):717– 726. PMID: 12509688 https://doi.org/10.1136/pmj.78.926.717Basit H, Malik A, Huecker MR. Non ST Segment Elevation (NSTEMI) Myocardial Infarction. [Last Update: September 6, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/ NBK513228/ [Accessed November 22, 2021].Basit H, Malik A, Huecker MR. Non ST Segment Elevation (NSTEMI) Myocardial Infarction. [Last Update: September 6, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK513228/ [Accessed Nov 22, 2021].Goyal A, Zeltser R. Unstable Angina. [Last Update: July 26, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK442000/ [Accessed November 22, 2021].Goyal A, Zeltser R. Unstable Angina. [Last Update: July 26, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK442000/ [Accessed Nov 22, 2021].Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST Elevation Myocardial Infarction. [Last Update: August 9, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532281/ [Accessed November 22, 2021].Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST Elevation Myocardial Infarction. [Last Update: August 9, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532281/ [Accessed Nov 22, 2021].Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–269. https://doi.org/10.1093/eurheartj/ehy462Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–269. https://doi.org/10.1093/eurheartj/ehy462Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation. 1995;92(3):657–671. PMID: 7634481 https://doi.org/10.1161/01. CIR.92.3.657Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation. 1995;92(3):657–671. PMID: 7634481 https://doi.org/10.1161/01.CIR.92.3.657Карагодин В.П., Бобрышев Ю.В., Орехов А.Н. Воспаление, иммунокомпетентные клетки, цитокины — роль в атерогенезе. Патогенез. 2014;12(1):21–35.Karagodin VP, Bobryshev YV, Orekhov AN. Inflammation, Immune Cells, Cytokines – Role in Atherogenesis. Patogenez. 2014;12(1):21–35. (in Russ.)Аронов Д.М., Лупанов В.П. Некоторые аспекты патогенеза атеросклероза. Атеросклероз и дислипидемии. 2011;1(2):48–56.Aronov DM, Lupanov VP. Atherosclerosis and Coronary Heart Disease: Some Aspects of Pathogenesis. Journal of Atherosclerosis and Dyslipidemias. 2011;1(2):48–56. (in Russ.)Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatmen. Circulation. 2017;136(12):1155– 1166. PMID: 28923905 https://doi.org/10.1161/CIRCULATIONAHA.117.029870Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatmen. Circulation. 2017;136(12):1155– 1166. PMID: 28923905 https://doi.org/10.1161/CIRCULATIONAHA.117 .029870O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction: a report of the ACCF/AMA Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425. PMID: 23247304 https://doi.org/10.1161/CIR.0b013e3182742cf6O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction: a report of the ACCF/AMA Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425. PMID: 23247304 https://doi.org/10.1161/CIR.0b013e3182742cf6Mekaj Y, Daci F, Mekaj A. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag. 2015;11:1449–1456. PMID: 26445544 https://doi.org/10.2147/TCRM.S92222Mekaj Y, Daci F, Mekaj A. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag. 2015;11:1449–1456. PMID: 26445544 https://doi.org/10.2147/TCRM.S92222Layne K, Ferro A. Antiplatelet Therapy in Acute Coronary Syndrome. Eur Cardiol. 2017;12(1):33–37. PMID: 30416549 https://doi.org/10.15420/ecr.2016:34:2Layne K, Ferro A. Antiplatelet Therapy in Acute Coronary Syndrome. Eur Cardiol. 2017;12(1):33–37. PMID: 30416549 https://doi.org/10.15420/ecr.2016:34:2Cattaneo M. ADP receptor antagonists. In: Michelson AD. (ed.) Platelets. 2nd ed. San Diego: Elsevier/Academic Press; 2007. Prt.5, Ch.61. p.1127– 1144. https://doi.org/10.1016/B978-012369367-9/50823-5Cattaneo M. ADP receptor antagonists. In: Michelson AD. (ed.) Platelets. 2nd ed. San Diego: Elsevier/Academic Press; 2007. Prt.5, Ch.61. p.1127– 1144. https://doi.org/10.1016/B978-012369367-9/50823-5Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533. PMID: 11520521 https://doi.org/10.1016/s0140-6736(01)05701-4Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533. PMID: 11520521 https://doi.org/10.1016/s0140-6736(01)05701-4Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607– 1621. PMID: 16271642 https://doi.org/10.1016/S0140-6736(05)67660-XChen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607– 1621. PMID: 16271642 https://doi.org/10.1016/S0140-6736(05)67660-XShuvanan R. Clopidogrel resistance: the way forward. Indian Heart J. 2014;66(5):530–534. PMID: 25443607 https://doi.org/10.1016/j.ihj.2014.08.012Shuvanan R. Clopidogrel resistance: the way forward. Indian Heart J. 2014;66(5):530–534. PMID: 25443607 https://doi.org/10.1016/j.ihj.2014.08.012Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56(18):1456–1462. PMID: 20832963 https://doi.org/10.1016/j.jacc.2010.03.100Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56(18):1456–1462. PMID: 20832963 https://doi.org/10.1016/j.jacc.2010.03.100Granger CB, Berger PB. Understanding the Adverse Effects of Ticagrelor in Practice. JAMA Cardiol. 2016;1(4):381–383. PMID: 27438332 https://doi.org/10.1001/jamacardio.2016.1018Granger CB, Berger PB. Understanding the Adverse Effects of Ticagrelor in Practice. JAMA Cardiol. 2016;1(4):381–383. PMID: 27438332 https://doi.org/10.1001/jamacardio.2016.1018Dellborg M, Bonaca MP, Storey RF, Steg PG, Kyung AI, Cohen M, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUSTIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):200–206. PMID: 31218354 https://doi.org/10.1093/ehjcvp/pvz020Dellborg M, Bonaca MP, Storey RF, Steg PG, Kyung AI, Cohen M, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUSTIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):200–206. PMID: 31218354 https://doi.org/10.1093/ehjcvp/pvz020Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357–374. PMID: 18078435 https://doi.org/10.1111/j.1527-3466.2007.00027.xJakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357–374. PMID: 18078435 https://doi.org/10.1111/j.1527-3466.2007.00027.xWiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. PMID:17982182 https://doi.org/10.1056/NEJMoa0706482Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. PMID:17982182 https://doi.org/10.1056/NEJMoa0706482De Luca L, Capranzano P, Patti G, Parodi G. Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. Am Heart J. 2016;176:44–52. PMID: 27264219 https://doi.org/10.1016/j.ahj.2016.03.006De Luca L, Capranzano P, Patti G, Parodi G. Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. Am Heart J. 2016;176:44–52. PMID: 27264219 https://doi.org/10.1016/j.ahj.2016.03.006Deerhake ME, Tricoci P. Vorapaxar: The Drug and its Applications. May 18, 2016. American college of cardiology. Available at: https://www.acc.org/latest-in-cardiology/articles/2016/05/18/13/58/vorapaxar [Accessed November 23, 2021].Deerhake ME, Tricoci P. Vorapaxar: The Drug and its Applications. May 18, 2016. American college of cardiology. Available at: https://www.acc.org/latest-in-cardiology/articles/2016/05/18/13/58/vorapaxar [Accessed Nov 23, 2021].Offermanns S. Activation of platelet function through G proteincoupled receptors. Circ Res. 2006;99(12):1293–1304. PMID: 17158345 https://doi.org/10.1161/01.RES.0000251742.71301.16Offermanns S. Activation of platelet function through G proteincoupled receptors. Circ Res. 2006;99(12):1293–1304. PMID: 17158345 https://doi.org/10.1161/01.RES.0000251742.71301.16Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23(18):1441–1448. PMID: 12208224 https://doi.org/10.1053/euhj.2002.3160Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23(18):1441–1448. PMID: 12208224 https://doi.org/10.1053/euhj.2002.3160Quinn MJ, Plow EF, Topol EJ. Platelet Glycoprotein IIb/IIIa Inhibitors, Recognition of a Two-Edged Sword? Circulation. 2002;106(3):379–385. PMID: 12119257 https://doi.org/10.1161/01.CIR.0000019581.22812.B2Quinn MJ, Plow EF, Topol EJ. Platelet Glycoprotein IIb/IIIa Inhibitors, Recognition of a Two-Edged Sword? Circulation. 2002;106(3):379–385. PMID: 12119257 https://doi.org/10.1161/01.CIR.0000019581.22812.B2Eisen A, Bhatt DL Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. Heart. 2017;103(11):871–884. PMID: 27888209 https://doi.org/10.1136/ heartjnl-2015-309022Eisen A, Bhatt DL Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. Heart. 2017;103(11):871–884. PMID: 27888209 https://doi.org/10.1136/heartjnl-2015-309022Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. PMID: 28886621 https://doi.org/10.1093/eurheartj/ehx393Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. PMID: 28886621 https://doi.org/10.1093/eurheartj/ehx393Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. PMID: 11519503 https://doi.org/10.1056/NEJMoa010746Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. PMID: 11519503 https://doi.org/10.1056/NEJMoa010746Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–1034. PMID: 28290994 https://doi.org/10.1016/S0140-6736(17)30397-5Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–1034. PMID: 28290994 https://doi.org/10.1016/S0140-6736(17)30397-5Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735–1749. PMID: 27022822 https://doi.org/10.1001/jama.2016.3775Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735–1749. PMID: 27022822 https://doi.org/10.1001/jama.2016.3775Sabouret P, Rushton-Smith SK, Kerneis M, Silvan J, Collet J-P, Montalescot G. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):198–204. PMID: 27533996 https://doi.org/10.1093/ehjcvp/pvv015Sabouret P, Rushton-Smith SK, Kerneis M, Silvan J, Collet J-P, Montalescot G. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):198–204. PMID: 27533996 https://doi.org/10.1093/ehjcvp/pvv015Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573–580. PMID: 28249994 https://doi.org/10.1136/heartjnl-2016-309871Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573–580. PMID: 28249994 https://doi.org/10.1136/heartjnl-2016-309871Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804– 810. PMID: 28363222 https://doi.org/10.1093/eurheartj/ehw525Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804– 810. PMID: 28363222 https://doi.org/10.1093/eurheartj/ehw525Шамраев Р.Л., Илюхин О.В., Иваненко В.В., Мерзляков С.Г., Лопатин Ю.М. Последствия эскалации и де-эскалации двойной антитромбоцитарной терапии у больных с острым коронарным синдромом в условиях реальной клинической практики. Российский кардиологический журнал. 2019;24(3):90–97. http://dx.doi.org/10.15829/1560-4071-2019-3-90-97Shamraev RL, Ilyukhin OV, Ivanenko VV, Merzlyakov SG, Lopatin YuM. Consequences of escalation and de-escalation of double antiplatelet therapy in patients with acute coronary syndrome in real clinical practice. Russian Journal of Cardiology. 2019;(3):90–97. (in Russ.) https://doi.org/10.15829/1560-4071-2019-3-90-97Kupka D, Sibbing D. De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention. Korean Сirc J. 2018;48(10):863–872. https://doi.org/10.4070/kcj.2018.0255Kupka D, Sibbing D. De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention. Korean Сirc J. 2018;48(10):863–872. https://doi.org/10.4070/kcj.2018.0255Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on Switching Platelet P2Y12 ReceptorInhibiting Therapies. Circulation. 2017;136(20):1955–1975. PMID: 29084738 https://doi.org/10.1161/CIRCULATIONAHA.117.031164Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on Switching Platelet P2Y12 ReceptorInhibiting Therapies. Circulation. 2017;136(20):1955–1975. PMID: 29084738 https://doi.org/10.1161/CIRCULATIONAHA.117.031164Deharo P, Quilici J, Camoin-Jau L, Johnson TW, Bassez C, Bonnet G. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPICVASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC Cardiovasc Interv. 2017;10(24):2560–2570. PMID: 29268886 https://doi.org/10.1016/j.jcin.2017.08.044Deharo P, Quilici J, Camoin-Jau L, Johnson TW, Bassez C, Bonnet G. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPICVASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC Cardiovasc Interv. 2017;10(24):2560–2570. PMID: 29268886 https://doi.org/10.1016/j.jcin.2017.08.044Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56(13):1017–1023. PMID: 20846599 https://doi.org/10.1016/j.jacc.2010.02.072Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56(13):1017–1023. PMID: 20846599 https://doi.org/10.1016/j.jacc.2010.02.072Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–1199. PMID: 20194878 https://doi.org/10.1161/CIRCULATIONAHA.109.919456Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–1199. PMID: 20194878 https://doi.org/10.1161/CIRCULATIONAHA.109.919456Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, et al. Inhospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv. 2014;7(4):585–593. PMID: 25097196 https://doi.org/10.1161/CIRCINTERVENTIONS.114.00 1555Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, et al. Inhospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv. 2014;7(4):585–593. PMID: 25097196 https://doi.org/10.1161/CIRCINTERVENTIONS.114.001555Kim H-S, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, et al. Prasugrelbased de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOSTREDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396(10257):1079–1089. PMID: 32882163 https://doi.org/10.1016/S0140-6736(20)31791-8Kim H-S, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, et al. Prasugrelbased de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOSTREDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396(10257):1079–1089. PMID: 32882163 https://doi.org/10.1016/S0140-6736(20)31791-8Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J. 2017;183:62–68. PMID: 27979043 https://doi.org/10.1016/j.ahj.2016.10.006Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J. 2017;183:62–68. PMID: 27979043 https://doi.org/10.1016/j.ahj.2016.10.006

The authors declare that there are no conflicts of interest present.